FDA Slaps Import Ban on Fifth Ranbaxy Facility

Generic Line
A A
Ranbaxy’s regulatory woes deepened last week as the FDA on Jan. 23 prohibited its Toansa, India, plant from making and distributing active pharmaceutical ingredients for U.S. products.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00